We have recently moved the
Creative Class Exchange.

Please update your bookmarks with our new address at www.creativeclass.com

We look forward to your comments and discussion.

Thank you.

Posts by Author

  • Global Trends
  • Ask Rana: Advice on Work, Life and Play
  • Urban Digs, Creative Class Communities
  • Workplace
  • Entrepreneurship, Creative Class Strategies
  • Creative Class Research and Indicators
  • Architecture + Design

Video Interview

Watch a Speech

Hear a Speech




February 03, 2007

« Super (Bowl) Cities | Main | Globalization of modeling »

An oped in today's Washington Post got me thinking about the global geography of science. The piece by  Brock Reeve, executive director of the Harvard Stem Cell Institute, and Joseph Fuller, Monitor Group founder, argues that a combination of political interference, lack-luster research support, and restrictive patents threaten America's lead in  stem cell research (the full piece after the jump).

Could we be experiencing a shift in the geography of global science?  The evidence of such a shift is beginning to accumulate.  At the top of the list is the increasingly active efforts of global universities and national governments to support cutting-edge research.  In the US frankly, research support is getting harder and harder to come by. Great foreign talent is having a harder and harder time getting into the country whether for graduate or post-graduate work or simply to go to a conference or workshop.  A recent Milken Institute report documents growing global competition in this area.  The global scientific system is no longer dominated by a handful of leading universities, lots of places can and do compete in specific fields.

It's' amazing how fast scientific leads can shift, actually. The US was a relative backwater until the middle part of the 20th century, before which British and German science were clear cut leaders. The Depression and World War II vaulted the US into a dominant position from which Britain and especially Germany have yet to recover.

But what's going on today seems different - and bigger perhaps - than a passing of the baton from one nation to another.  It's not as if any one country will overtake the US.  Lots of places are now doing very good science. The system itself seems to be changing, becoming more global in character. The main factor driving this is the global nature of the  labor market for scientific talent.  Scientists are incredibly mobile. They  go where the best people are, where the best science is done, where research funding is plentiful, and where opportunities for breakthroughs abound.

Seems to me that the scientific system is no longer nationally based but truly global in character, taking shape around concentrated spikes of excellence. If this is so, it means the existing structure for nationally-based funding is inefficient and out-of-whack really, given the fluid mobility of leading scientific talent.

Could we be experiencing the beginnings of a not just a shift in national and institutional leadership, but of a more thoroughgoing transformation of the global scientific system? If so, this would provide not only an opportunity to rethink scientific institutions on a more global basis but would provide an interesting test case on how to build global institutions more generally.

Your thoughts?

Will We Lose in the Stem Cell Race?

By Joseph Fuller and Brock Reeve
Washington Post
Saturday, February 3, 2007;  Page A15

Americans take it for granted that they are the world's leaders in the life sciences. And it's true that, today, American companies account for 60 percent of global pharmaceutical sales and 75 percent of biotech sales, and that they dominate the market for medical devices. But complacency is a powerful enemy; our leadership position is not a national birthright. We could fumble it just as we fumbled leadership in the consumer electronics and automotive sectors." (read the rest after the jump).

In science and technology-intensive fields, fumbling is particularly easy. Less than 30 years ago, five of the world's top 10 pharmaceutical companies, including the two largest, were European. Between 1980 and 1984, Europe invented more than half of the world's new drugs. Observers assumed that Europe would lead the anticipated revolution in biotechnology.

Today, however, American companies account for more than three-quarters of worldwide biotech revenue and have almost 4,500 products in development -- 2 1/2 times as many as European companies.

How did we turn the tables?

· Government actions and court decisions allowed the patenting of living organisms and made it possible for private researchers to commercialize discoveries funded by federal grants. Further, Stanford University, which controlled key patents, ensured their widespread and rapid adoption.

· In Europe, the countries of the European Union had independent regulators until the 1990s. The patentability of living organisms remained uncertain until 1998. And state-funded academic institutions had little incentive to encourage academics to pursue commercially oriented research.

· Between 1985 and 1995 the U.S. government invested more than $50 billion in the biological sciences. Federal spending during that period dwarfed the amount spent in Europe and encouraged private-sector investment.

· With the availability of affordable, fundamental patents and a supportive public policy environment, between 1987 and 1997 investors bet some $6 billion of risk capital on the fledging sector in the United States, roughly five times as much as their European counterparts.

Can we repeat that success in new areas of science, such as stem cell research? Many Americans assume that once the current restrictions on federal funding of embryonic stem cell research have been lifted, America will surge to the forefront. A quick glance at the field seems to bear that out. The fundamental patents underlying embryonic stem cell research were developed in the United States and are held by the Wisconsin Alumni Research Foundation (WARF). Many leading scientists are based in this country. With private philanthropy supporting institutions such as the Harvard Stem Cell Institute, and public money in states including California, New Jersey, Connecticut and Maryland supporting research, history seems poised to repeat itself.

But closer examination suggests that such confidence might be misplaced. If one analyzes the state of the industry along some of the same critical dimensions that contributed to our come-from-behind win in biotechnology, unnerving patterns emerge.

· While Stanford granted 73 nonexclusive licenses in less than a year, WARF has awarded just 13 licenses in eight years under economic terms that many believe have slowed the sector's growth.

· The ongoing political debate over the appropriate use of embryonic stem cells and the low level of government support have denied stem cell research the catalyst provided to biotechnology -- even as other countries are investing aggressively.

· The entry of individual states into the breach left by the federal government has helped drive research activity. But it has also created a patchwork of regulations and funding levels that constrains research collaboration.

· Expensive and restrictive enabling patents, political controversy and the absence of federal research money, coupled with a long time to market, have made venture capitalists reluctant to invest. In 2005, just over $100 million in venture capital went to stem cell ventures, compared with $500 million in biotech ventures at an equivalent stage.

· Constraining federal research support to a selected area -- such as certain cell types and lines -- is not a sensible research policy. Advances with stem cells from amniotic fluid and the pulp of baby teeth have been in the news recently, but as the authors of those studies point out, such cells, while promising, cannot take the place of embryonic cells. These restrictions divert valuable time and effort in a way that is not occurring in Britain or Singapore.

In short, the stem cell sector is at risk of experiencing a failure to launch at the national level. Yes, some progress is being made: WARF has just revised some of its licensing policies; venture capital activity has picked up recently; and academic research and clinical centers, disease foundations and patient-advocacy groups are adopting a more aggressive stance in breaking down existing barriers. But will this be enough? Or will foreign governments, using America's biotech success as a model, systematically encourage the development of stem cell research and, not satisfied with emulating our competitive performance, succeed in outstripping us?


TrackBack URL for this entry:

Listed below are links to weblogs that reference New geography of science:


Alex Soojung-Kim Pang

The idea that "the scientific system is no longer nationally based but truly global in character, taking shape around concentrated spikes of excellence" matches conclusions we at the Institute for the Future have reached in our work on the future of science and technology (published at http://www.deltascan.org). Smaller, well-educated countries or regions are developing strategies of targeted global excellence-- not competing with the US or UK in nanotechnology or computer science, say, but focusing on enhanced fabrics or mobile computing platforms.

This lets smaller players change the rules of the game, avoiding direct competition with big countries; it also creates some "stickiness" that-- in theory, anyway-- could slow scientific talent from moving away so quickly.


Alex--I can't wait to read your work. I see Demos has been doing some research in this area as well.

We agree. This is the same kind of strategy Dick Cyert, Herb Simon and othersm pioneered 25-30 years ago at Carnegie Mellon, where I witnessed its results first-hand. Focus on niches, they emphasized, especially at the intersection of disciplines where less work has been done and big hits are more likely.

I am also thinking more and more about tTwenty or thirty years ago most young professors were married with families. Many, if not most, were of their country's nationality, even in the US. Now an increasing percentage are single and they are from all corners of the world.

These changes may cut in favor of urban universities in large cosmopolitan cities, not just in Europe but around the world. Especially since many college town locations in the US can no longer insulate themselves from the culture and policies of their surrounding states. Michigan's retreat on domestic partner benefits is a case in point.

When I was on the market, people were looking at great universities in college towns throughout the Midwest. Heck I went to Ohio State and flourished there. But today, young scholars have options around the world. Ohio State, Iowa, Wisconsin, etc. are in effect competing head to head with rapidly improving universities in Europe, Asia and elsewhere. Today, someone coming out of school may be weighing offers at Midwestern universities and say Hong Kong or Singapore or Sydney. Many might increasingly take those more cosmopolitan universities. And virtually all my foreign born graduate students say they will return home when they have families, for reasons I've discussed on this blog.

In any event, it is increasingly the case that both university quality and location matter, and this advantages some places over others.

Bill Hoffman

Our world stem cell policy map will accompany reprints of the excellent article by Joseph Fuller and Brock Reeve (above).


The geography of bioscience, as suggested by the article and by Richard and Alex, is an area that policymakers are just beginning to grapple with. It is not at all a stretch to suggest, as Richard does, that the global scientific system is facing a major transformation.


This web-site is the coolest! Now I dont have to feel so intimated by science! Youre a genius! I think Ill visit this site often.


This is a cool site! Thanks and wish you better luck! Brilliant but simple idea.


ho! get go!


I like it and the background and colors make it easy to read.


Thank you for good job!


I have not understood your message.


Beautiful site!


je n'arive pas le"Techno L2" kes ki fau faire svp !!!


It was a great pleasure for me to visit and enjoy your site. Keep it running!


like your site ! Its very well !


You are the best! Im glad...


Very cool!
nice work!
Girls, have fun, not boys
I have already enjoy your website, and it is so nice and cool. I will visit your website again. Thank you. Please More updates
Nice site! Big thanx to webmaster!

msuza qucrfvnyd

gzjr jzlqifv wuhkv ljvzxqdg hgamin ceyklf gcqusdw


Some individuals have chosen laundry baskets, planters, or small trashcans to serve as the base of a gift basket. All the other accessories can be rented at the agency itself. When creating a custom-made gift basket, the first thing to do is select a container, such as a wicker-type vessel. [url=http://stanleylaughlin.hostingtribe.com/house2535.html]book synopsis of safe house[/url] [url=http://ashonalfred.tripod.com/house789.html]the pump houseflorida[/url]

The comments to this entry are closed.